Phase II Trial of REVLIMID (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas

Trial Profile

Phase II Trial of REVLIMID (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2017

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Thyroid cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Dec 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 11 Dec 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 04 Jun 2017 Planned End Date changed from 1 Dec 2015 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top